FDA approves Cobenfy: A breakthrough Schizophrenia treatment after decades

The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the first new type of medication in decades that alleviates symptoms without common side effects. Available by late October, the drug will cost $1,850 monthly before insurance and rebates.